Propanc Biopharma Inc., based in Melbourne, is a biopharmaceutical company that is developing new cancer treatments for the patients that are suffering from recurring or metastatic cancer. The company has announced the receiving of a granted United States patent from the United States Patent and Trademark Office (USPTO) that covers the composition of matter claims including trypsinogen and chymotrypsinogen.
The granted patent that is issued by the USPTO is now conferring exclusive rights to the lead product of the company, PRP, by showing that the compositions that are comprised of trypsinogen and chymotrypsinogen are exhibiting a synergistic ability for inhibiting the growth of several cancer cell lines.
The Chief Executive Officer of Propanc, Mr. James Nathanielsz said that they continued to grow and strengthen their portfolio of intellectual property and that it was very pleasing to receive more patent claims for the PRP in one of their most significant global jurisdictions. He said that currently, they had 65 patents in major global regions that were either in the force or pending around the world, and this was very important as they advanced PRP towards the human trials.
The Chief Scientific Officer of Propanc, Dr. Julian Kenyon said that they continued to fund research programs with their university partners, and also planned to file more patent applications in the future. Kenyon added that the intellectual property lied at the heart of any primary stage Biotech company and they looked forward to expand their portfolio that covered further aspects of their invention that was related to PRP, more so as they advanced further down the pathway of clinical development.